Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
$0.00
$0.00
$0.00
N/A1.98N/AN/A
Affymax Inc. stock logo
AFFY
Affymax
$0.00
$0.00
$0.00
$0.00
N/A7.341,916 shsN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
$0.00
$0.00
$0.02
N/A3.856 shsN/A
DGEN
Deltagen
$0.00
$0.00
$0.00
N/AN/AN/AN/A
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00%0.00%0.00%0.00%0.00%
Affymax Inc. stock logo
AFFY
Affymax
0.00%0.00%+700.00%-66.67%+14.29%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00%0.00%0.00%0.00%-98.75%
DGEN
Deltagen
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
DGEN
Deltagen
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
0.00
N/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
0.00
N/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
0.00
N/AN/AN/A
DGEN
Deltagen
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/AN/A
DGEN
Deltagen
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/A0.00N/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
-$2.11MN/A0.00N/AN/AN/AN/AN/AN/A
DGEN
Deltagen
N/AN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/AN/AN/AN/AN/A
Affymax Inc. stock logo
AFFY
Affymax
N/AN/AN/AN/AN/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/AN/AN/AN/AN/A
DGEN
Deltagen
N/AN/AN/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
N/A
Affymax Inc. stock logo
AFFY
Affymax
N/A
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
N/A
DGEN
Deltagen
N/A

Insider Ownership

CompanyInsider Ownership
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
17.40%
Affymax Inc. stock logo
AFFY
Affymax
1.55%
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
28.20%
DGEN
Deltagen
46.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alliqua BioMedical, Inc. stock logo
ADYX
Alliqua BioMedical
6N/AN/ANot Optionable
Affymax Inc. stock logo
AFFY
Affymax
4N/AN/ANot Optionable
Adhera Therapeutics, Inc. stock logo
ATRX
Adhera Therapeutics
211.63 million8.35 millionNot Optionable
DGEN
Deltagen
150N/AN/ANot Optionable

Recent News About These Companies

No headlines for this company have been tracked by MarketBeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alliqua BioMedical stock logo

Alliqua BioMedical OTCMKTS:ADYX

Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.

Affymax stock logo

Affymax OTCMKTS:AFFY

$0.0008 0.00 (0.00%)
As of 07/3/2025

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Adhera Therapeutics stock logo

Adhera Therapeutics OTCMKTS:ATRX

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Deltagen OTCMKTS:DGEN

Deltagen Inc. provides drug discovery tools and services to the biopharmaceutical industry. The company offers a suite of programs designed to enhance the efficiency of drug discovery, including access to biological models, as well as small-molecule and secreted protein drug targets. It also provides target validation data in the areas of immunology and metabolic diseases. The company was incorporated in 1999 and is headquartered in San Mateo, California.